Two abortion‑pill makers have asked the Supreme Court to lift a Fifth Circuit order that blocks nationwide mail delivery of mifepristone. Danco Laboratories filed the emergency request Saturday, and partner GenBioPro said it will follow. The appellate panel reinstated an in‑person prescribing rule that was relaxed in 2021, effectively halting a key telemedicine channel for patients. The filing cites immediate patient harm.

Telemedicine now accounts for roughly one‑quarter of U.S. abortions, and the mail route has become a lifeline in states with strict bans. Louisiana sued the FDA, arguing the 2021 rule change was based on flawed data and spurred illegal abortions. The Trump administration, while defending the agency, has delayed a safety review until year‑end, keeping the policy in limbo. The case also reverberates in upcoming elections.

The dispute threatens the revenue streams of Danco and GenBioPro, whose products generate hundreds of millions annually, and could destabilize a burgeoning telehealth market valued at billions. Investors watch the Supreme Court’s response closely, as a reversal would restore a major distribution channel, while an affirmation of the Fifth Circuit could force providers to redesign service models nationwide. Regulatory clarity remains the sector’s top priority.